Please login to the form below

Not currently logged in

Verona appoints chief financial officer

Richard Bungay brings experience from Chroma, Celltech and AstraZeneca

Verona Pharma Richard BungayVerona has named Richard Bungay as the company's chief financial officer to replace Danny Lowe.

Bungay joins the UK-based biotech initially on a part-time basis as it looks to develop its portfolio of investigational medicines for respiratory diseases.

His most recent position was as part-time CEO of fellow UK biotech Chroma Therapeutics, which focuses on the development of novel small molecules for inflammation and oncology, having previously served as the company's chief financial officer.

Prior to his time at Chroma, Bungay was director of corporate communications and strategic planning at Celltech and spent several years as finance director within the respiratory and inflammation therapy area at AstraZeneca.

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: "Richard's experience in financial management of innovative R&D-based businesses as well as his experience in investor relations will be invaluable to Verona Pharma as we move our key clinical programmes forward and grow the company.”

10th September 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...